Molecular antigen array

Details Molecular antigen array Molecular antigen array

2005-11-15

2005-11-15

Mosher, Mary E. (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C424S193100, C424S194100, C424S196110, C424S278100, C424S281100, C530S350000, C530S402000, C530S403000, C530S404000, C530S405000, C530S408000, C530S807000

Reexamination Certificate

active

06964769

ABSTRACT:
The invention provides compositions and processes for the production of ordered and repetitive antigen or antigenic determinant arrays. The compositions of the invention are useful for the production of vaccines for the prevention of infectious diseases, the treatment of allergies and the treatment of cancers. Various embodiments of the invention provide for a core particle that is coated with any desired antigen in a highly ordered and repetitive fashion as the result of specific interactions.

REFERENCES:
patent: 4722840 (1988-02-01), Valenzuela et al.
patent: 4959314 (1990-09-01), Mark et al.
patent: 5071651 (1991-12-01), Sabara et al.
patent: 5143726 (1992-09-01), Thornton et al.
patent: 5334394 (1994-08-01), Kossovsky et al.
patent: 5374426 (1994-12-01), Sabara et al.
patent: 5565548 (1996-10-01), Neurath et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5698424 (1997-12-01), Mastico et al.
patent: 5739026 (1998-04-01), Garoff et al.
patent: 5766602 (1998-06-01), Xiong et al.
patent: 5770380 (1998-06-01), Hamilton et al.
patent: 5789245 (1998-08-01), Dubensky, Jr. et al.
patent: 5792462 (1998-08-01), Johnston et al.
patent: 5814482 (1998-09-01), Dubensky, Jr. et al.
patent: 5871747 (1999-02-01), Gengoux-Sedlik et al.
patent: 5928647 (1999-07-01), Rock
patent: 5935821 (1999-08-01), Chatterjee et al.
patent: 6004763 (1999-12-01), Gengoux et al.
patent: 6054312 (2000-04-01), Larocca et al.
patent: 6231864 (2001-05-01), Birkett
patent: 2004/0059094 (2004-03-01), Bachmann et al.
patent: 2004/0076611 (2004-04-01), Bachmann et al.
patent: 2004/0076645 (2004-04-01), Bachmann et al.
patent: 0 259 149 (1988-03-01), None
patent: 0 283 505 (1988-09-01), None
patent: 0 385 610 (1990-05-01), None
patent: 0 425 082 (1991-05-01), None
patent: 0 465 081 (1992-01-01), None
patent: 0 578 293 (1994-01-01), None
patent: 0 385 610 (1994-03-01), None
patent: WO 92/11291 (1992-07-01), None
patent: WO 94/06472 (1994-03-01), None
patent: WO 94/15585 (1994-07-01), None
patent: WO 96/05293 (1996-02-01), None
patent: WO 96/30523 (1996-10-01), None
patent: WO 97/31948 (1997-09-01), None
patent: WO 98/15631 (1998-04-01), None
patent: 98/40100 (1998-09-01), None
patent: WO 99/07839 (1999-02-01), None
patent: WO 99/28478 (1999-06-01), None
patent: WO 99/40934 (1999-08-01), None
patent: WO 99/50432 (1999-10-01), None
patent: WO 99/57289 (1999-11-01), None
patent: WO 99/67293 (1999-12-01), None
patent: WO 00/32227 (2000-06-01), None
patent: WO 00/50461 (2000-08-01), None
Pasek et al (Nature 282, 575-579, 1979).
Zhou et al (Journal of Virology 66(9): 5393-5398, 1992).
Abraham, J.M., et al., “An invertible element of DNA controls phase variation of type 1 fimbriae ofEscherichia coli,” Proc Natl Acad Sci U S A. Sep. 1985;82(17):5724-5727, National Academy Press (1985).
Abraham, S.N., et al., “Glycerol-induced unraveling of the tight helical conformation ofEscherichia colitype 1 fimbriae,”J Bacteriol. Aug. 1992;174(15):5145-5148, American Society for Microbiology (1992).
Amon, R., et al., “A mimotope peptide-based vaccine againstSchistosoma mansoni: synthesis and characterization,”Immunology. Dec. 2000;101(4):555-562, Blackwell Science, Ltd. (Dec. 2000).
Bachmann, M.F., et al., “TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation,”J Exp Med. Apr. 5, 1999;189(7):1025-1031, The Rockefeller University Press (1999).
Bass, S., and Yang, M., “Expressing cloned genes inEscherichia coli,”Protein Function: A practical Approach, 2nded., Creighton, T.E., ed., IRL Press, Oxford, Great Britain, pp. 29-55 (1997).
Blomfield, I.C., et al., “Type 1 fimbriation and fimE mutants ofEscherichia coliK-12.,”J Bacteriol. Sep. 1991;173(17):5298-5307, American Society for Microbiology (1991).
Blomfield, I.C., et al., “Integration host factor stimulates both FimB- and FimE-mediated site-specific DNA inversion that controls phase variation of type 1 fimbriae expression inEscherichia coli,” Mol Microbiol. Feb. 1997;23(4):705-717, Blackwell Science, Ltd. (1997).
Boder, E.T., and Wittrup, K.D., “Yeast surface display for directed evolution of protein expression, affinity, and stability,”Methods Enzymol. 2000;328:430-444, Academic Press (Oct. 2000).
Bonci, A., et al., “Relatedness and phylogeny within the family of periplasmic chaperones involved in the assembly of pili or capsule-like structures of gram-negative bacteria,”J Mol Evol. Mar. 1997;44(3):299-309, Springer Verlag New York Inc. 1997.
Brinton, Jr., C.C., “the Structure, function, synthesis and genetic control of bacterial pili and a molecular model for DNA and RNA transport in gram negative bacteria,”Trans. N.Y. Acad. Sci. 1965;27:1003-1054, New York Academy of Sciences (1965).
Brown, K.D., et al., “A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes,”J Immunol. Jan. 15, 1989;142(2):679-687, The American Association of Immunologists (1989).
Brown, P.M., et al., “A single-step purification of biologically active recombinant human interleukin-5 from a baculovirus expression system,”Protein Expr Purif. Feb. 1995;6(1):63-71, Academic Press, Inc. (1995).
Burger, J.A., et al., “Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1,”Blood. Oct. 2000;96(8):2655-63, The American Society of Hematology (Oct. 2000).
Burghoff, R.L., et al., “Utilization of the mouse large intestine to select anEscherichia coliF-18 DNA sequence that enhances colonizing ability and stimulates synthesis of type 1 fimbriae,”Infect Immun. Apr. 1993;61(4):1293-1300, American Society for Microbiology (1993).
Daugherty, P.S. et al., “Development of an optimized expression system for the screening of antibody libraries displayed on theEscherichia colisurface,”Protein Eng. Jul. 1999;12(7):613-621, Oxford University Press (Jul. 1999).
Eisenstein, B.I., et al., “Phase variation of type 1 fimbriae inEscherichia coliis under transcriptional control,”Science, Oct. 16, 1981;214(4518):337-339, American Association for the Advancement of Science (1981).
Elisseeva, E.L., et al., “NMR studies of active N-terminal peptides of stromal cell-derived factor-1. Structural basis for receptor binding,”J Biol Chem. Sep. 1, 2000;275(35):26799-26805, The American Society for Biochemistry and Molecular Biology Inc. (Sep. 2000).
Fehr, T., et al., “T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles,”Proc Natl Acad SciU S A. Aug. 4, 1998;95(16):9477-9481, National Academy Press (1998).
Gally, D.L., et al., “Environmental regulation of the fim switch controlling type 1 fimbrial phase variation inEscherichia coliK-12: effects of temperature and media,”J Bacteriol. Oct. 1993;175(19):6186-6193, American Society for Microbiology (1993).
Gally, D.L., et al., “Interaction of FimB and FimE with the fim switch that controls the phase variation of type 1 fimbriae inEscherichia coliK-12,”Mol Microbiol. Aug. 1996;21(4):725-38, Blackwell Science Ltd: (1996).
Gherardi, E., et al., “A single-step procedure for cloning and selection of antibody-seceting hybridomas,”J Immunol Methods. Jan. 24, 1990;126(1):61-68, Elsevier (1990).
Hanes, J., et al., “Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display,”Nat Biotechnol, Dec. 2000;18(12):1287-1292, Nature Publishing Company (Dec. 2000).
Hanson, M.S., et al., “Purification of theEscherichia colitype 1 pillin and minor pilus proteins and partial characterization of the adhesin protein,”J Bacteriol. Aug. 1968;170(8):3350-3358, American Society for Microbiology

Affiliated with

Also associated with

Rating

Molecular antigen array does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Molecular antigen array, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Molecular antigen array will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3495090